Feb. 13, 2008--Introgen Therapeutics, Inc. (NASDAQ:INGN) and Moffitt Cancer Center today announced that a randomized, controlled study of INGN 225, Introgen's immunotherapy product has been initiated in patients with metastatic small-cell lung cancer (termed extensive stage SCLC).Introgen and Moffitt previously announced that the National Institutes of Health National Cancer Institute awarded a grant of approximately $1.3 million to fund the trial based upon the promising results of previous clinical studies in small-cell lung cancer patients.
INGN 225 is a p53 immunotherapy using a patient's own cells to stimulate an anti-tumor immune response to fight cancer. The immunotherapeutic targets the p53 tumor suppressor molecular abnormality found in over half of all solid cancers... Introgen's Press Release -
